ACADIA Pharmaceuticals Inc (ACAD) reports a 32% annual revenue increase, driven by strong sales of DAYBUE and NUPLAZID, while expanding its pipeline and preparing for European market entry.

Talk about a heavy dose. While the bulk of news coverage is focused on GLP-1 drugs like Ozempic that cause weight loss, ...

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Paranoid symptoms and severe aggression, which represent a danger to the individual and to others, warrant the use of atypical antipsychotics after their relative risks and benefits have been ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

A brain scan can’t detect bipolar disorder. Mental health professionals typically use diagnostic interviews. Brain scans are still important for bipolar disorder research. MRI and CT scans can ...

Including additional features, such as genetic markers, comorbid medical conditions, and psychosocial factors, may enhance the model’s ability to predict treatment outcomes. Multimodal data ...

Global Frontotemporal Disorders Treatment Market is valued at approximately USD $$ billion in 2022 and is anticipated to grow with a healthy growth rate of more than $% over the forecast period ...

The potential for false-positive UDS results was identified for the following medication classes on the clinic formulary: antihistamines, antidepressants, antibiotics, analgesics, antipsychotics ...

This is referred to as treatment-resistant schizophrenia. Medications to treat schizophrenia come in four forms: Second-generation antipsychotics First-generation antipsychotics Long-acting injectable ...

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. A sustained ...